Status:

RECRUITING

The Gut-Brain Axis During Neurorehabilitation; Prebiotic Treatment to Alter the Gut Microbiome and Neurologic Symptoms

Lead Sponsor:

The University of Texas Medical Branch, Galveston

Collaborating Sponsors:

Moody Neurorehabilitation Institute

Conditions:

Brain Injuries

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The aim of this study is to characterize the microbiome of patients undergoing post-acute residential neurorehabilitation compared to community controls and to determine if a dietary fiber, Inulin, ca...

Detailed Description

The investigative research team previously described Brain Injury Associated Fatigue and Altered Cognition (BIAFAC) as a treatable syndrome that occurs in a subset of patients following traumatic brai...

Eligibility Criteria

Inclusion

  • Brain Injury Patients
  • Inclusion
  • Ages 18 and above
  • Admitted to Moody Neurorehabilitation Institute for care
  • Less than 6 months post-injury
  • English speaking
  • Must be able to eat and drink by mouth
  • Willing and able to comply with study procedures
  • Willing and able to provide consent (with LAR if needed)
  • Exclusion
  • Significant heart, liver, kidney, blood or respiratory disease
  • HIV, Hepatitis B or Hepatitis C
  • Pregnancy or becoming pregnant during the study
  • History of inflammatory bowel disease
  • History of celiac disease
  • Active diverticular disease
  • Known allergy to study agent
  • Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation
  • Community Control Subjects
  • Inclusion
  • Ages 18 and above
  • Have a family member who is admitted to Moody Neurorehabilitation Institute for care OR is working at Moody Neurorehabilitation Institute
  • English speaking
  • Willing and able to comply with study procedures
  • Willing and able to provide consent
  • FACs score ≤ 50
  • Exclusion
  • Trauma to head in last 6 months
  • Stroke in last 6 months
  • Significant heart, liver, kidney, blood or respiratory disease
  • HIV, Hepatitis B or Hepatitis C
  • Pregnancy or becoming pregnant during the study
  • History of inflammatory bowel disease
  • History of celiac disease
  • Active diverticular disease
  • Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation

Exclusion

    Key Trial Info

    Start Date :

    March 6 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    October 1 2028

    Estimated Enrollment :

    130 Patients enrolled

    Trial Details

    Trial ID

    NCT06607523

    Start Date

    March 6 2025

    End Date

    October 1 2028

    Last Update

    December 19 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Texas Medical Branch

    Galveston, Texas, United States, 77555